By SIRION Biotech…
To get in touch with SIRION Biotech promote progress of novel breakthrough vaccines at BIO-Europe, simply fill out the form below.
Subscribe to Supplier
SIRION Biotech promote progress of novel breakthrough vaccines at BIO-Europe
Martinsried, Germany: – Viral technology specialist SIRION Biotech will bring details of its breakthrough vaccines to November’s prestige BIO-Europe biotechnology partnering conference in Munich.
The SIRION team, led by CEO Dr. Christian Thirion, will show how its new production cell lines have managed to produce high yields of its novel DNA viral vectors associated with toxic antigens, which have hitherto been difficult to express.
“We believe our work means that very soon will there be novel breakthrough vaccines in the market,” said. Dr. Thirion.
“Associating vaccines with just prophylaxis will soon be a paradigm of the past. Increasingly, vaccines will demonstrate therapeutic effects specifically in the field of so far difficult to address tumor diseases and immune therapies,” he commented.
HEK293 genetic modification
A critical hurdle has in the past been making enough of the vaccine vector material. This is especially difficult when the viral or bacterial origin of antigens makes them potentially toxic, as is the case with the majority of HIV envelope proteins and bacterial virulence factors.
Over a two-year development project, SIRION Biotech has applied genetic modification to widespread and inexpensive HEK293 cells to suppress specific antigen production. This novel cell line overcomes production issues related to all DNA-based viral vectors that express toxic proteins during the process. The technology is generally applicable to the production of DNA-vector based vaccines and can be applied to common vaccine production cell lines.
Cancer immune therapies
SIRION Biotech has combined its new antigens with innovative invariant chain adjuvant technology developed by Prof. Peter Holst of University of Copenhagen in the quest for novel cancer immune therapies.
The co-development has been based on SIRION’s lead candidate Ad19a as novel adenovirus serotype with promising immune response-stimulating activity. A preclinical safety and efficacy study will soon evaluate a treatment vaccine based on this technology against established HPV infections.
About SIRION Biotech
Founded at Martinsried, near Munich, in 2007, SIRION BIOTECH has become Europe’s leading commercial supplier of viral vectors used for genetic research, clinical target validation, gene therapy and vaccination studies.
From the beginning, SIRION’s mission has been to change the paradigm for viral vector supplies, with ability to develop and supply all common viral vector types (adenovirus, lentivirus, AAV, etc.) within a matter of weeks at the concentration titers and quantities needed for preclinical human and animal testing.
The company also offers a full range of virus related services, ranging from particle production to virus driven cell modeling.
SIRION offerings include the transformational RNAiONE™ knockdown validation platform.
SIRION’s core expertise lies in custom virus generation for genetic engineering of mammalian cell systems. With its comprehensive viral vector portfolio, SIRION offers a suitable option for almost any in vitro and in vivo application. SIRION can supply all three of the most commonly used virus systems for gene manipulation: recombinant adenovirus particles (AVs), lentiviruses and adeno-associated viruses (AAVs).
About BIO-Europe 2015
The BIO-Europe® Conference is the flagship conference for EBD Group, providing life science companies with high caliber knowledge sharing and partnering opportunities.
BIO-Europe 2015 event is a three-day event opening November 2 at Munich’s ICM international conference center.
BIO-Europe has formed the launchpad for many highly successful business partnerships, drawing delegates from all parts of the biotechnology value chain to identify, engage and enter into strategic relationships.
This year´s BIO-Europe partnering event will again draw over 3,000 industry attendees from nearly 60 countries, representing more than 1,800 companies for three days of high level networking.
Partnering at BIO-Europe 2015 is powered by EBD Group’s partnering ONE®, the industry’s most advanced networking system, which enables participants to efficiently mine a large pool of potential partners, and identify and pre-arrange private one-to-one meetings with multiple company targets.
More information at: www.ebdgroup.com/bioeurope/index.php